Compugen Pockets $3.6M from Evogene Share Sale | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen has sold nearly half of its stake in Evogene, pocketing around $3.6 million from the share sale, the Tel Aviv, Israel-based firm said today.

Compugen said that it sold one million shares in a private transaction to a single, unidentified purchaser. It said that proceeds from the sale would be used to fund general corporate purposes through mid-2010.

Following the sale, Compugen holds 1,150,000 shares of Evogene, which uses Compugen's in silico predictive discovery capabilities for agricultural applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.